SCAI has diversified its planning committees and expanded the focus on live cases for its 2019 scientific sessions, says Program Chair Sunil Rao, MD.

After a successful safety and feasibility trial run, the FDA granted approval April 26 to the STEMI DTU (ST-Elevation Myocardial Infarction Door-to-Unloading) study, which will examine whether unloading the left ventricle prior to reperfusion can reduce myocardial damage and lead to fewer CV complications in STEMI patients.

A little less than half of atherosclerotic cardiovascular disease (ASCVD) patients are treated for blood cholesterol according to 2013 clinical guidelines, with around half missing out on a statin prescription the guidelines would have recommended, according to a study published in the American Journal of Cardiology.

The latest drug company to issue a recall of losartan is Teva Pharmaceuticals, which on April 29 announced it was recalling 35 lots of the popular blood pressure medication.

The FDA on May 1 announced it cleared Medtronic’s Attain Stability Quad MRI SureScan left heart lead for commercial use in the U.S.

Research out of the University of Manchester suggests Tadalafil (Cialis)—an erectile dysfunction drug that falls in the same class as Viagra—could slow and possibly reverse the progression of heart failure (HF).

The addition of 2.4% hydrogen to hypoxia patients’ traditional ventilation gases improved neurologic outcomes and reduced tissue injury in a recent study of piglets, suggesting hydrogen might be a beneficial addition to therapy for babies undergoing surgery for congenital heart disease (CHD).

Intensive therapy to keep blood pressure (BP) levels below 130/80 mmHg helped lower the risk for heart attacks, strokes and other CV complications in patients with concomitant type 2 diabetes and hypertension, researchers have found.